Initial Statement of Beneficial Ownership (3)
September 24 2014 - 4:34PM
Edgar (US Regulatory)
CONFIRMING STATEMENT
This Statement confirms that the undersigned has authorized and
designated the Chief Executive Officer, the Chief Financial Officer
or the Chief Operating Officer of Galectin Therapeutics Inc (the
"Company") to execute and file on the undersigned's behalf all Forms 3
4 and 5 (including any amendments thereto) that the undersigned may be
required to file with the U.S. Securities and Exchange Commission as a
result of the undersigned's ownership of or transactions in securities
of the Company. The authority of the Chief Executive Officer, the Chief
Financial Officer or the Chief Operating Officer of the Company under
this Statement shall continue until the undersigned is no longer
required to file Forms 3 4 and 5 with regard to the undersigned's
ownership of or transactions in the securities of the Company unless
earlier revoked in writing The undersigned acknowledges that the
Chief Executive Officer, the Chief Financial Officer or the Chief
Operating Officer of the Company is not assuming any of the
undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934.
Dated as of September 23 2014 /s/ Gilbert S. Omenn
Signature
Gilbert S. Omenn
Print Name
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2024 to May 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From May 2023 to May 2024